Home / Brand archive
25 reported ongoing
103 records in this archive. Latest source date Aug 6, 2026.
FDA enforcement status can lag behind the recall lifecycle. An empty search or a reported termination is not a personal product-safety determination.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
Subpotent Drug: Assay below the approved specification
Class IIReported ongoing
Distribution: Nationwide in the USA
Subpotent
Class IIReported ongoing
Distribution: Nationwide US.
Subpotent
Class IIReported ongoing
Distribution: Nationwide US.
Subpotent
Class IIReported ongoing
Distribution: Nationwide US.
Subpotent
Class IIReported ongoing
Distribution: Nationwide US.
Subpotent drug
Class IIReported terminated
Distribution: USA Nationwide
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Class IIReported terminated
Distribution: Nationwide in the USA and PR
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Class IIReported terminated
Distribution: Nationwide in the USA and PR
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Class IIReported terminated
Distribution: Nationwide in the USA and PR
Failed Impurities/Degradation Specifications.
Class IIReported terminated
Distribution: Nationwide within the United States and PR
Subpotent drug: out of specification results
Class IIIReported terminated
Distribution: USA Nationwide
Presence of Particulate Matter: Particulate matter identified as fiber.
Class IIReported terminated
Distribution: Nationwide within the United States
Presence of Particulate Matter: Particulate matter identified as fiber.
Class IIReported terminated
Distribution: Nationwide within the United States
Sub-potent drug: assay test result below specifications at 9-month timepoint.
Class IIIReported terminated
Distribution: Nationwide in the USA.
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIReported terminated
Distribution: United States including Puerto Rico and Canada
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIReported terminated
Distribution: United States including Puerto Rico and Canada
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIReported terminated
Distribution: United States including Puerto Rico and Canada
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIReported terminated
Distribution: United States including Puerto Rico and Canada
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIReported terminated
Distribution: United States including Puerto Rico and Canada
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIReported terminated
Distribution: United States including Puerto Rico and Canada
These examples come from this result page and are not a ranking of every recall reason.
This archive contains 103 records, including 25 with agency-reported ongoing status. The status field can be incomplete or stale. Open the current official notice and match your exact product.
Compare the product, firm and lot, date, model or serial identifiers with the notice. Use the label-check guide if you need help locating an identifier.
A name is a search match. The agency notice sets the affected products and identifiers. Do not assume that every item with the same name or brand belongs to the recall.
This search has source and keyword limits. Missing records or a missing lot code do not establish that a product is unaffected. Check source coverage and the agency's current notices.
Use monthly archives or the local search. The initial import covers records dated from October 2021 where available; each source's actual first and latest dates appear on the coverage page.